PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource, 1 online resource.

Language: Englisch

Bibliographic citation: PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer ; volume:28 ; number:1 ; day:9 ; month:6 ; year:2023 ; pages:1-12 ; date:12.2023
Journal of mammary gland biology and neoplasia ; 28, Heft 1 (9.6.2023), 1-12, 12.2023

Creator: Amante, Romain J.
Jehanno, Charly
Silva, Duvini De
Coissieux, Marie-May
Ackerknecht, Markus
Romanet, Vincent
Sethi, Atul
Hamelin, Baptiste
Preca, Bogdan-Tiberius
Piscuoglio, Salvatore
Ng, Charlotte K. Y.
Mohseni, Morvarid
Bentires-Alj, Mohamed

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10911-023-09539-9

URN: urn:nbn:de:101:1-2023091909190658446549

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:51 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Amante, Romain J.
Jehanno, Charly
Silva, Duvini De
Coissieux, Marie-May
Ackerknecht, Markus
Romanet, Vincent
Sethi, Atul
Hamelin, Baptiste
Preca, Bogdan-Tiberius
Piscuoglio, Salvatore
Ng, Charlotte K. Y.
Mohseni, Morvarid
Bentires-Alj, Mohamed
SpringerLink (Online service)

Other Objects (12)

Metastatic Triple-Negative Breast Cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

Metastatic Triple-Negative Breast Cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

Metastatic Triple-Negative Breast Cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Metastatic Triple-Negative Breast Cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

Metastatic Triple-Negative Breast Cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

Metastatic Triple-Negative Breast Cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

Related objects

Reset password